Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Biopharma venture funding dropped 20% in the first quarter of 2025 compared to the same period the year before, according to ...

The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing.  | The National ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Chris Smyth, Ph.D., is leaving his post as president of Icon Biotech to take the helm at Comac Sept. 1, the company said in ...

GE HealthCare trimmed its financial forecasts for the remainder of the year in the face of U.S. | GE HealthCare said that ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Parkinson’s disease has always been a complex puzzle, for patients and researchers alike, with contributing factors ranging ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

An investor is ratcheting up the pressure on Acelyrin to pull out of a planned merger with Alumis, setting out its case for ...